<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922932</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB#00016932</org_study_id>
    <nct_id>NCT03922932</nct_id>
  </id_info>
  <brief_title>WF and PR OCTA in Diabetic Retinopathy</brief_title>
  <official_title>Wide-Field and Projection-Resolved Optical Coherence Tomography Angiography in Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is a leading cause of vision loss in working-age Americans.&#xD;
      Capillary damage from hyperglycemia causes vision loss through downstream effects, such as&#xD;
      retinal ischemia, edema, and neovascularization (NV). Proper screening and timely treatment&#xD;
      with laser photocoagulation and anti-vascular endothelial growth factor (VEGF) injections can&#xD;
      minimize morbidity. In the last decade, clinicians have been able to use objective structural&#xD;
      data from optical coherence tomography (OCT) to guide the treatment of diabetic macular&#xD;
      edema. Other aspects of care, however, still largely depend on subjective interpretation of&#xD;
      clinical features and fluorescein angiography (FA) to determine the disease severity and&#xD;
      treatment threshold. The recently developed OCT angiography (OCTA) provides dye-less,&#xD;
      injection-free, three-dimensional images of the retinal and choroidal circulation with high&#xD;
      capillary contrast. Not only is it safer, faster, and less expensive than conventional&#xD;
      dye-based angiography, OCTA provides the potential of giving clinicians objective tools for&#xD;
      determining severity of disease by detecting and quantifying NV and non-perfusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PR-OCTA Measure of Non-Perfusion Areas</measure>
    <time_frame>3 years</time_frame>
    <description>Non-perfusion areas of the 3 retinal plexuses and choriocapillaris will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-PR-OCTA Measure of Retinal Non-Perfusion Areas</measure>
    <time_frame>1 year</time_frame>
    <description>Non-perfusion areas of the 3 retinal plexuses will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-PR-OCTA Retinal Neovascularization Areas</measure>
    <time_frame>1 year</time_frame>
    <description>Retinal neovascularization areas will be measured in mm2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural OCT Cyst Volume</measure>
    <time_frame>1 year</time_frame>
    <description>Cyst volume will be measured in mm3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural OCT Retinal Thickening Area</measure>
    <time_frame>1 year</time_frame>
    <description>The area of retinal thickening will be measured in mm2.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Group A: PDR</arm_group_label>
    <description>This group will consist of 25 subjects with active proliferative diabetic retinopathy (PDR) and 25 subjects with treated PDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: NPDR</arm_group_label>
    <description>This group will consist of 50 subjects with severe non-proliferative diabetic retinopathy (NPDR), 50 subjects with moderate NPDR, and 50 subjects with mild NPDR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group ME: Macular Edema</arm_group_label>
    <description>This group is a sub-set of 25 subjects from either Group A or B who have macular edema requiring treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: DM without Retinopathy</arm_group_label>
    <description>This group will consist of 50 subjects with diabetes mellitus (DM) who do not have retinopathy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Healthy Controls</arm_group_label>
    <description>This group will consist of 40 subjects with healthy eyes who do not have diabetes.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults age 18 or older with either healthy eyes or diabetic retinopathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Participant-Related Inclusion Criteria:&#xD;
&#xD;
        I. All Diabetics (Groups A, B, C)&#xD;
&#xD;
          -  Type 1 diabetes of at least 5 years duration or&#xD;
&#xD;
          -  Type 2 diabetes of any duration II. Group B&#xD;
&#xD;
          -  Able to return for follow-up over 3 years&#xD;
&#xD;
        Participant-Related Exclusion Criteria:&#xD;
&#xD;
        I. Group B&#xD;
&#xD;
          -  Significant medical condition that would make long-term follow-up difficult II.&#xD;
             Controls (Group D)&#xD;
&#xD;
          -  Any medical problems associated with retinal vascular abnormalities (i.e.,&#xD;
             hypertension, systemic vasculitis, carotid insufficiency, etc.)&#xD;
&#xD;
        Eye-Related Inclusion Criteria:&#xD;
&#xD;
        I. Group A:&#xD;
&#xD;
          -  Presence of active neovascularization, with or without prior treatment&#xD;
&#xD;
          -  Presence of involuted fibrovascular proliferans&#xD;
&#xD;
        II. Group B:&#xD;
&#xD;
          -  NPDR of any severity as defined by the International Clinical Diabetic Retinopathy&#xD;
             Severity Scale&#xD;
&#xD;
        III. Groups C &amp; D:&#xD;
&#xD;
          -  No evidence of diabetic retinopathy&#xD;
&#xD;
        IV. Group ME:&#xD;
&#xD;
          -  Presence of center-involving macular edema requiring treatment&#xD;
&#xD;
        Eye-Related Exclusion Criteria: (Applies to study eye only. May be present in non-study&#xD;
        eye.)&#xD;
&#xD;
          -  Visual acuity worse than 20/200&#xD;
&#xD;
          -  Inability to maintain stable fixation for OCT imaging&#xD;
&#xD;
          -  History of major eye surgery (vitrectomy, cataract surgery, scleral buckle, other&#xD;
             intraocular surgery, etc.) within 90 days of enrollment&#xD;
&#xD;
          -  History of another eye disease or condition that may alter retinal perfusion,&#xD;
             permeability, or retinal anatomy&#xD;
&#xD;
          -  Substantial media opacity (cataract, corneal scar, vitreous hemorrhage) that may&#xD;
             interfere with study imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Lathrop</last_name>
    <phone>503-494-8024</phone>
    <email>lathropk@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denzil Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Lathrop</last_name>
      <phone>503-494-8024</phone>
      <email>lathropk@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denzil Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Lauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Bailey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phoebe Lin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John P Campbell, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Flaxel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kavita Bhavsar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merina Thomas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Thomas Hwang, MD, Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>OCT</keyword>
  <keyword>Angiography</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

